Dr. Barry Dworkin

A Phase-1 vaccine study result should not be used to extrapolate efficacy. It is designed to determine the vaccine’s safety profile. Patience required for the results of the next two trial phases to truly answer the efficacy question.

Medical Mythbusting Commentary for July 15, 2020

Source:

Covid-19 vaccine hopes raised as trial of Moderna’s experimental jab shows ALL 45 injected volunteers developed antibodies

Related posts:

  1. Moderna Says Its New COVID-19 Vaccine Protects Against the BA.2.86 Variant
  2. Parent claims to be assessed in court about alleged H1N1 vaccine side effects and its responsibility in the death of their daughter.
  3. Early days with Phase 1 trial of SARS-Coronavirus vaccine.
  4. Does Oxford-AstraZeneca vaccine increase risk of blood clots? To conclude this would require evidence that incidence exceeds what is normally expected in the general population. To date, this is not the case according to reports from health authorities.